Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 3Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Ichthyosis, X-Linked 1HER2 Negative Metastatic Breast Cancer 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 58Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 25Irinotecan 24Carboplatin 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × ADI PEG20 × Clear all
NCT00029900 2015-03-25

ADI-PEG in Patients With Metastatic Melanoma

FDA Office of Orphan Products Development

Phase 1 Completed
15 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡